AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Bone Marrow TransplantationBone MarrowTransplantation, HomologousBone Marrow CellsGraft vs Host DiseaseTransplantation, AutologousHematopoietic Stem Cell TransplantationWhole-Body IrradiationTissue DonorsTransplantation ConditioningGraft SurvivalBone and BonesTransplantation ChimeraAnemia, AplasticLeukemiaLiver TransplantationHematopoietic Stem CellsBusulfanHistocompatibility TestingHistocompatibilityBone Marrow PurgingTransplantation, IsogeneicCyclophosphamideHematopoiesisHematologic NeoplasmsRadiation ChimeraKidney TransplantationBone Marrow DiseasesMice, Inbred C57BLRecurrenceGraft RejectionCombined Modality TherapyTreatment OutcomeLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositiveImmunosuppressive AgentsStem Cell TransplantationTime FactorsTransplantation ImmunologyRemission InductionPrecursor Cell Lymphoblastic Leukemia-LymphomaBone Marrow ExaminationSevere Combined ImmunodeficiencyLymphocyte DepletionHepatic Veno-Occlusive DiseaseImmunosuppressionGraft vs Host ReactionLeukocyte TransfusionLeukemia, MyeloidChimeraBone RemodelingLiving DonorsAcute DiseaseColony-Forming Units AssayT-LymphocytesHLA AntigensBone Marrow NeoplasmsLymphoma, Non-HodgkinHeart TransplantationRetrospective StudiesCord Blood Stem Cell TransplantationSurvival AnalysisMyelodysplastic SyndromesHematologic DiseasesAntigens, CD34Lymphocyte TransfusionCyclosporineBlood DonorsCell DifferentiationLung TransplantationGranulocyte Colony-Stimulating FactorActuarial AnalysisGraft vs Tumor EffectGraft vs Leukemia EffectAntineoplastic Combined Chemotherapy ProtocolsNuclear FamilyFlow CytometryChimerismSurvival RateBone DensityMice, Inbred BALB CCytomegalovirus InfectionsLeukocyte CountFollow-Up StudiesSpleenOrgan TransplantationCarmustineMelphalanPancytopeniaHematopoietic Stem Cell MobilizationCytarabineDisease-Free SurvivalCells, CulturedPeripheral Blood Stem Cell TransplantationMultiple MyelomaIslets of Langerhans TransplantationGraft Enhancement, ImmunologicLymphomaCell TransplantationAntilymphocyte Serum
Cell transplantationTransplantGVHDAutologousBlood and Marrow TransplantationNeutrophil engraftmentChemotherapyPeripheral bloodPediatricProgenitor cellsHematologyUmbilicalMatched unrelated donor transplantationOutcomeChimerismPatientsEfficacyOutcomesReactivationHuman hematopoieticInfusionClinicalTransplantsGraftMortalityComplicationsAllogeneic HSCTCord-bloodProphylaxisImmuneAplastic anemiaCurative treatmentProliferateAbstractRecipientsHematologicalHSCsInfectionAdultAlloreactive donorHaploidentical donorsLiver transplantationMedianLymphoproliferative disordersCyclophosphamideCentreDiseasesRecipientProliferation
Cell transplantation47
Transplant33
  • Non-myeloablative, so-called mini transplant (microtransplantation) procedures, have been developed requiring smaller doses of preparative chemotherapy and radiation therapy, allowing HSCT to be conducted in the elderly and other patients who would otherwise be considered too weak to withstand a conventional treatment regimen. (wikipedia.org)
  • The Worldwide Network for Blood and Marrow Transplantation reported the millionth transplant to have been undertaken in December 2012. (wikipedia.org)
  • Allogeneic transplants involve grafts from a genetically nonidentical donor of the same species and are the transplant type most often used in children. (oncologynurseadvisor.com)
  • The second obstacle was the availability of transplant donors. (nih.gov)
  • To try to make transplantation safer we are using lower doses of the medications used in preparing the patient for the transplant. (zhihuiya.com)
  • At day 100 after the transplant a sample of bone marrow is taken. (zhihuiya.com)
  • Building off experience in hematopoietic stem cell transplant and exploiting advances in genetic engineering, genome editing, immunology, immunotherapy, stem cell biology, understanding disease mechanisms and cell therapy manufacturing, considerable progress has been made with hundreds of clinical trials underway. (bdbiosciences.com)
  • Therefore, we sought to translate these results to a clinically relevant canine-to-canine allogeneic transplant model for Duchenne muscular dystrophy (DMD) and determine if CXCR4 is important for donor cell engraftment. (biomedcentral.com)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease (GVHD) prevention strategy in haploidentical hematopoietic cell transplant (haplo-HCT). (biomedcentral.com)
  • Second, the use of the patient's own bone marrow cells for gene replacement does not result in graft-versus-host disease (GVHD), a major complication of current allogeneic transplant. (nih.gov)
  • Third, use of autologous hematopoietic stem cells would be expected to enhance immune reconstitution after transplant. (nih.gov)
  • We are evaluating whether allogeneic HSCT can reconstitute normal hematopoiesis in MonoMAC and reverse the hematological abnormalities in MDS, if MDS is present at the time of transplant. (nih.gov)
  • In the mid-20th century, Dr. E. Donnall Thomas achieved a landmark breakthrough by successfully performing the first bone marrow transplant between identical twins in 1956 (Thomas et al. (revistadehematologia.org.mx)
  • In April 1960, Dr. Álvaro Gómez-Leal, presented during the first meeting of the Agrupación Mexicana para el Estudio de la Hematología, A.C., data on a transplant of allogeneic stem cells in a patient with acute leukemia done in Monterrey, Mexico: the patient received high-dose chemotherapy followed by stem cells from the bone marrow of his brother, improving and obtaining remission for months but relapsing and subsequently died. (revistadehematologia.org.mx)
  • It was only until 1988 when the same group could report on their first successful bone marrow transplant (León-Rodríguez et al. (revistadehematologia.org.mx)
  • Acute Graft-versus-host disease (GvHD), one of the major complications of HSCT, is correlated to conditioning-induced gut barrier damage and may be predicted by pre-transplant serum citrulline level (Rashidi, BBMT 2018). (confex.com)
  • Two patients died early, and the remaining patients experienced neutrophil engraftment in a median of 17 days (range, 10-36) post-transplant. (hematologyadvisor.com)
  • Professor Ma holds leadership or scientific membership positions in a number of national and international scientific communities including the World Network for Blood & Marrow Transplantation (a WHO affiliated NGO), the AsiaPacific BM Transplant and the Royal College of Pathology of Australasian Quality Assurance Programme. (edu.au)
  • Researchers at Children's Hospital of Philadelphia (CHOP) have developed a custom-built application to automate determination of engraftment, a key outcome after hematopoietic stem cell transplant (HSCT). (azolifesciences.com)
  • The application supersedes a tedious manual process and at the same time substantially improves accuracy of reported hematopoietic cell transplant engraftments. (azolifesciences.com)
  • Hematopoietic stem cell (HSC) transplant, also referred to as bone marrow or stem cell transplant, is a complex process used for the treatment of multiple types of malignant and non-malignant diseases in adults and children. (azolifesciences.com)
  • For that reason, federal law requires that clinicians report time to engraftment for all transplants to the Center for International Blood and Marrow Transplant Research (CIBMTR). (azolifesciences.com)
  • Director of Bone Marrow Transplant and Cell Therapies, Royal Manchester Children's Hospital, United Kingdom. (ebmt.org)
  • T-replete mismatched cord blood transplant (TRCB) offers an augmented graft versus leukemia (GVL) effect mediated by alloreactive donor T cells and thereby presents a potential for long term remission and cure in high risk and relapsed refractory AML in children. (ebmt.org)
  • Due to advances in transplant approaches and supportive care, the use of HSCT is increasing worldwide. (hindawi.com)
  • Despite such a progress, HSCT is still associated with substantial transplant-related mortality (TRM). (hindawi.com)
  • The authors studied the first viral pathogen detected within 100 days of transplantation in 738 allogeneic hematopoietic cell transplant patients at the University of Michigan Medical Center to determine if they might be associated with IPS or other outcomes. (hhv-6foundation.org)
  • Following up on the work done by investigators at Washington University who characterized murine roseolovirus as a mouse homolog of HHV-6 and HHV-7 ( Patel 2017 ), Xiaofeng Zhou, PhD, infected newborn mice with MRV and later performed a bone marrow transplant (BMT) protocol after 8-10 weeks to reactivate the virus. (hhv-6foundation.org)
  • Recently published data suggest that enteral nutrition (EN), given as systematic artificial nutrition support, could decrease grade III-IV graft-versus-host disease (GVHD) and infectious events, which are associated with early toxicity after allo-HSCT and then have an impact on early transplant-related mortality (D100 mortality). (biomedcentral.com)
  • The impacts of nutritional support should exceed the limits of nutritional status improvement: EN may directly reduce immunological and infectious events, as well as decrease early transplant-related morbidity and mortality. (biomedcentral.com)
  • Transplant infectious disease : an official journal of the Transplantation Society 2022 6 24 (4): e13879. (cdc.gov)
GVHD18
  • Treatment focuses on blocking the expansion of donor T cells, as GVHD develops from the expansion of these cells. (oncologynurseadvisor.com)
  • Recent studies are investigating the efficacy of rituximab (Rituxan) for GVHD in pediatric HSCT patients. (oncologynurseadvisor.com)
  • GvHD is commonly associated with bone marrow transplants and stem cell transplants . (wikipedia.org)
  • Graft-versus-host disease (GvHD) prophylaxis consisted of a short course of methotrexate and cyclosporin A. Neutrophil and platelet engraftment occurred on days 22 and 65 after surgery, respectively. (cdc.gov)
  • Despite prophylactic treatment of the patients with immunosuppressive drugs after allo-HSCT, GvHD is still associated with non-relapse mortality (NRM) and contributes around 25% of NRM. (frontiersin.org)
  • Thus, prophylactic transfusion of donor T-cells has been included in many protocols, despite the increased risk for acute GvHD ( Kolb, 2008 ). (frontiersin.org)
  • HSCT patients are presumed immunocompetent if they are at least 24 months post-HSCT, are not receiving immunosuppressive therapy, and do not have graft- versus-host disease (GVHD). (cdc.gov)
  • These results suggested that ATG/PTCy (low-dose) can reduce both acute and chronic GVHD as compared with standard ATG-based prophylaxis using maternal donor or collateral relatives at particular high GVHD risk. (biomedcentral.com)
  • Recently, we established a regimen using low-dose PTCy in conjunction with standard-dose ATG in order to lower the risk of GVHD without compromising engraftment and disease relapse. (biomedcentral.com)
  • In addition, low-dose PTCy could augment the protective effect of ATG on GVHD both in mouse and human sets while ensuring high rates of engraftment and keeping disease control [ 18 ]. (biomedcentral.com)
  • 6 , 7 After UCB transplantation (UCBT), the incidence of GVHD is lower, that of leukemic relapse is similar, while the incidence of opportunistic infections is higher compared with BM transplantation or HSCT. (ashpublications.org)
  • The 3-year probability of total chronic graft-versus-host disease (GVHD) was 21.4% and 34.1% in the haploidentical and HLA-matched HSCT groups, respectively ( P =0.526). (blood-genomics.com)
  • Despite a huge progress in HSCT techniques and posttransplant care, GVHD remains a significant obstacle in successful HSCT outcome. (hindawi.com)
  • GVHD occurs in about 30-50% and 70% of recipients allografted from matched related and matched unrelated donors, respectively [ 1 ]. (hindawi.com)
  • The degree of HLA disparity between donor and recipient is a well-known and widely accepted independent risk factor for GVHD development [ 2 ]. (hindawi.com)
  • Inherited genetic variants such as single-nucleotide polymorphisms (SNPs) of candidate genes, encoding various cytokines, chemokines, and inflammatory regulators, have become a subject of interest of genetic studies searching for independent predictors of GVHD development and HSCT outcome [ 4 - 7 ]. (hindawi.com)
  • Acute GVHD occurs most frequently 30-40 days after engraftment. (hindawi.com)
  • The histocompatibility differences between the donor and the recipient, the presence of donor's immunocompetent cells, and the inability of the recipient to reject these cells were defined as the basic pathogenic prerequisites for GVHD development by Billingham in 1966 [ 10 ]. (hindawi.com)
Autologous8
  • It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin). (wikipedia.org)
  • Autologous HSCT requires the extraction (apheresis) of hematopoietic stem cells (HSCs) from the patient and storage of the harvested cells in a freezer. (wikipedia.org)
  • These advantages have established autologous HSCT as one of the standard second-line treatments for such diseases as lymphoma. (wikipedia.org)
  • In recent years, especially after the advent of reduced intensity conditioning in the late 1990s, allogeneic HSCT is increasingly used in older patients and as an effective salvage strategy for patients with lymphoma or myeloma not responding to chemotherapy or autologous HSCT. (longdom.org)
  • This article contains highlights of "Guidelines for Pre- allogeneic or autologous, depending on the source of venting Opportunistic Infections among Hematopoi- the transplanted hematopoietic progenitor cells. (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • First, the use of autologous hematopoietic stem cells for gene therapy obviates the need for a matched bone marrow donor since each individual would serve as his or her own bone marrow stem cell donor. (nih.gov)
  • Figure 1 shows the trend in the annual number of allogeneic and autologous HCTs in adults with AML reported in the Japanese transplantation registry. (apbmt.org)
Blood and Marrow Transplantation1
  • In 2006, 50,417 first HSCTs were recorded worldwide, according to a global survey of 1,327 centers in 71 countries conducted by the Worldwide Network for Blood and Marrow Transplantation. (wikipedia.org)
Neutrophil engraftment4
  • After neutrophil engraftment (day 22) and addition of erythromycin to the antimicrobial drug regimen, body temperature decreased and oxygen supplementation was discontinued. (cdc.gov)
  • Patients demonstrated a 5-year overall survival rate of 86%, with all but 2 patients achieving neutrophil engraftment. (hematologyadvisor.com)
  • In a prospective analysis from April 2021 to April 2022, the researchers found that neutrophil engraftment reporting was found to be incorrect in only 2 of 53 cases (3.8%), both of which were due to typographical errors and not the application, versus 15% of cases when engraftments were calculated manually prior to April 2021. (azolifesciences.com)
  • This was followed by neutrophil engraftment on day +19. (ebmt.org)
Chemotherapy9
  • In these cases, the recipient's immune system is usually destroyed with radiation or chemotherapy before the transplantation. (wikipedia.org)
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient's malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient's bone marrow's ability to grow new blood cells). (wikipedia.org)
  • Chemotherapy, radiation, or both are initiated prior to transplantation to enable engraftment of the transplanted cells, decrease tumor size, and reduce immunoreactivity of the recipient. (oncologynurseadvisor.com)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • 2009 ). The underlying mechanism of HBV flare and reactivation following HSCT is likely to be related to impaired cellular immunity caused by prior chemotherapy and conditioning regimens. (springeropen.com)
  • We determined if adoptive transfer of natural killer (NK) cells from haploidentical killer immunoglobulin-like receptor (KIR)-human leukocyte antigen (HLA)-mismatched donors may prolong event-free survival in children with intermediate-risk AML who were in first complete remission after chemotherapy. (biomedcentral.com)
  • Patients may alternatively receive lympho-depleting chemotherapy followed by adoptive transfer of purified NK cells from an alloreactive donor, resulting in homeostatic lymphocyte proliferation with transient donor NK cell expansion in recipients [ 7 ]. (biomedcentral.com)
  • Once the chemotherapy has cleared out the patient's HSCs, new HSCs from a donor are infused. (azolifesciences.com)
  • Allo-HSCT includes administration of a chemotherapy-based conditioning regimen (myelo-ablative or non-myelo-ablative), followed by infusion of alloreactive haematopoietic stem cells, with the aim of inducing an active immunological anti-tumoral effect. (biomedcentral.com)
Peripheral blood5
Pediatric5
  • SCID is considered a pediatric emergency because survival depends on expeditious stem cell reconstitution, usually by bone marrow transplantation (BMT). (medscape.com)
  • DESIGN/METHODS: To determine the cumulative incidence and review the clinical data of PTLD diagnosed in the cohort of pediatric patients (<18 years) who had liver transplantation performed between 1 January 2001 and 31 December 2012 in the major liver transplantation centre (Queen Mary Hospital) of Hong Kong. (hku.hk)
  • RESULTS: Among 75 cases of pediatric liver transplantation performed during the study period, 17 cases of PTLD (seven males) were diagnosed, giving cumulative incidence of 6.8% at 1 year and 22% at 5 years. (hku.hk)
  • This study analyzed the clinical outcomes of 119 pediatric acute leukemia patients who underwent haploidentical HSCT ( n =68) or human leukocyte antigen (HLA)-matched HSCT ( n =51). (blood-genomics.com)
  • The study suggests that haploidentical HSCT shows comparable OS, LFS, and GRFS to HLA-matched HSCT in pediatric patients with acceptable complications, and can therefore be recommended as an effective alternative for this population. (blood-genomics.com)
Progenitor cells2
  • The respective mice that reconstitute human immune system components upon transplantation with CD34+ human hematopoietic progenitor cells could recapitulate aspects of EBV and HIV immunobiology observed in dual-infected patients. (hku.hk)
  • Independent origins of fetal liver haematopoietic stem and progenitor cells. (u-tokyo-hemat.com)
Hematology1
  • Led by our Hematology/Oncology and Clinical Informatics fellow, David Anderson, MD, our team was rapidly able to build a custom tool that drastically reduced engraftment reporting error rates. (azolifesciences.com)
Umbilical3
Matched unrelated donor transplantation1
Outcome4
  • 2002 until 2007), two were included in TK007 (2005-2009) and six serves as a control group for outcome after haploidentical transplantation without HSV-TK-transduced DLI. (frontiersin.org)
  • 2 Most subsequent transplantations in IEM have been for Hurler syndrome (MPSIH), and it remains the most common IEM for which HSCT is indicated and performed and about which most is understood in terms of factors determining both graft and disease outcome. (ashpublications.org)
  • The presence of immune cells in UCB that are not directed against maternal foreign Ags is remarkable and may explain the reported clinical observation of improved HSCT outcome with younger sibling donors. (ashpublications.org)
  • 1 , 2 A recent study suggested that transplantation outcome can be improved by taking the birth order of siblings into account. (ashpublications.org)
Chimerism2
  • Donor chimerism was stabilized after transfusion of the transduced cells in all patients treated. (frontiersin.org)
  • We are also evaluating whether we achieve sufficient donor chimerism to reverse the MDS. (nih.gov)
Patients40
  • It is most often performed for patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia. (wikipedia.org)
  • Also, the incidence of patients experiencing rejection is very rare (and graft-versus-host disease impossible) due to the donor and recipient being the same individual. (wikipedia.org)
  • We compared outcomes of HSCT from HLA-identical (HLA-id, n = 1654) sibling or haploidentical (Haplo, n = 389) donors in patients with R/R-AML, performed during the period 2007-2015. (unisr.it)
  • 15% of patients with SCD have an HLA-matched sibling donor. (nih.gov)
  • [10] It is less common in younger patients and in those with closer human leukocyte antigens (HLA) matches between donor and the patient. (wikipedia.org)
  • The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. (frontiersin.org)
  • This study uses transplantation to treat patients with problems in their immune system. (zhihuiya.com)
  • Conditioning' treatments are given to patients to create space in their bone marrow. (zhihuiya.com)
  • Patients who do not have a matched sibling donor but have a donor that matches in the National Marrow Donor Program. (zhihuiya.com)
  • To create space in the bone marrow, patients are given two drugs, Campath-1H and busulfan. (zhihuiya.com)
  • On the day before the BMT, patients in the matched unrelated donor group also receive a low-dose of whole-body radiation. (zhihuiya.com)
  • This will further improve the chances that the patients body will accept the donor cells. (zhihuiya.com)
  • Patients will get the donor stem cells through an intravenous (IV) line that goes into a vein in their body. (zhihuiya.com)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
  • and phase mended strategies for preventing OIs in HSCT patients. (cdc.gov)
  • All patients but one in ATG cohort achieved myeloid engraftment by day 30 post-HCT. (biomedcentral.com)
  • While allogeneic HSCT is the conventional curative treatment for immunodeficiency and MDS, patients with MonoMAC, because of an intact T-cell population and co-existing infection, represent a profile not generally encountered in the setting of allogeneic HSCT. (nih.gov)
  • Dr. George Mathé explored the transplantation of bone marrow cells from healthy donors to treat patients accidentally irradiated at high dose, expanding the possibilities of this life-saving technique (Mathé et al. (revistadehematologia.org.mx)
  • Serum citrulline was quantified by liquid chromatography in blood samples collected from consecutive patients who received an allogeneic HSCT in our institution between July 2014 and November 2019. (confex.com)
  • The study was a retrospective analysis of 37 adult patients who received their first allogeneic HSCT for hepatitis-associated aplastic anemia between 1985 and 2014. (hematologyadvisor.com)
  • To examine the efficacy and tolerability of ETV treatment in HSCT, we retrospectively identified 5 patients who received ETV for treatment of HBsAg carrier among patients undergoing HSCT in our institute. (springeropen.com)
  • There were no episodes of HBV flare or reactivation after HSCT in all patients during the observation period, as a 10-fold rise in HBV DNA levels or positive conversion of HBsAg were not observed. (springeropen.com)
  • ETV monotherapy is effective and safe for HBsAg carrier patients following HSCT. (springeropen.com)
  • HBV-infected patients at high risk of HBV flare and reactivation are recommended to receive preemptive antiviral therapy following HSCT. (springeropen.com)
  • Several studies have reported the efficacy of LAM treatments in HSCT patients (Hsiao et al. (springeropen.com)
  • In fact, LAM treatments showed high resistance and recurrence rates in patients with chronic hepatitis B infection (CHB) undergoing liver transplantation (Perrillo et al. (springeropen.com)
  • Here, we describe HBsAg carrier patients administered ETV for treatment following HSCT, and consider its efficacy and tolerability. (springeropen.com)
  • We retrospectively identified HBsAg carrier patients (serum HBsAg-positive and HBV-DNA positive) who received ETV for prophylaxis of HBV flare among patients undergoing HSCT between September 2006 and August 2011. (springeropen.com)
  • Over the last years, transplantation outcomes have improved in this group of patients as the factors that predicted for poor transplantation outcomes were understood and addressed. (ashpublications.org)
  • In parallel with improvements in transplantation techniques, other therapies such as pharmacological enzyme replacement therapy (ERT), substrate inhibition, and gene therapy have been developed and are increasingly available to clinicians and their patients. (ashpublications.org)
  • For patients lacking matched sibling donors, haploidentical donors are an option. (blood-genomics.com)
  • This process involves collating records from different source systems and reviewing lengthy tables of lab results, which can be difficult, time-consuming, and error-prone, as the time to engraftment can vary based on whether patients had platelet transfusions, whether their neutrophil counts dipped sometime after infusion, and other variables that might be missed in manual review. (azolifesciences.com)
  • In the majority of patients, this disorder is typically characterized by infantile-onset hemophagocytic lymphohistiocytosis (HLH), which is lethal unless allogeneic transplantation is performed. (biomedcentral.com)
  • Improved outcomes of transplantation have been reported when performed before the development of HLH, thus it is important to quickly differentiate patients that present with the childhood form of disease and to prematurely enroll them into a transplantation protocol. (biomedcentral.com)
  • However, owing to the immense heterogeneity of patients' cohorts and progress in HSCT techniques in the last decade, many of reported results failed to be independently validated [ 6 , 8 , 9 ]. (hindawi.com)
  • Two hundred forty patients treated with allo-HSCT for a haematological malignancy will be randomly assigned to two groups to receive either EN or PN. (biomedcentral.com)
  • The American Society of Parenteral and Enteral Nutrition (ASPEN) and the French-speaking society of clinical nutrition and metabolism (SFNEP) recommend nutritional support during haematopoietic transplantation for patients who are malnourished or have decreased intake or decreased intestinal absorption over a prolonged period (grade B) [ 11 , 12 ]. (biomedcentral.com)
  • For practical and historical reasons, parenteral nutrition (PN) is often the first option chosen for patients undergoing an allo-HSCT [ 13 ]. (biomedcentral.com)
  • Indeed, allo-HSCT patients all have a central-venous access that facilitates PN administration. (biomedcentral.com)
  • Single-Nucleotide Polymorphisms Within Non-HLA Regions Are Associated With Engraftment Effectiveness for Patients With Unrelated Cord Blood Transplantation. (cdc.gov)
Efficacy5
  • Thus, we studied the safety, efficacy, and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte infusion (DLI). (frontiersin.org)
  • Therefore, these results establish the efficacy of diprotin A in stimulating muscle cell engraftment, and highlight the pre-clinical utility of a xenotransplantation model in assessing the relative efficacy of muscle stem cell populations. (biomedcentral.com)
  • The efficacy of HSCT extends to conditions beyond these well-established diseases. (revistadehematologia.org.mx)
  • Although Entecavir (ETV) is a standard antiviral drug for HBV infection, the efficacy and safety of ETV therapy in HSCT are still unclear. (springeropen.com)
  • The mechanism of transplantation efficacy in X-ALD is not by cross-correction of enzyme-deficient host cells by secreted enzyme, so this condition will be discussed separately at the end of this review. (ashpublications.org)
Outcomes3
Reactivation1
  • However, little information is available on the gene expression profile (GEP) of CMV-CTL clones according to CMV reactivation patterns (and donor CMV serostatus) after allo-HCT. (nature.com)
Human hematopoietic1
  • These results represent the first successful use of a foamy virus (FV) vector to treat a genetic disease, and they suggest that FV vectors will be effective in treating human hematopoietic diseases. (nih.gov)
Infusion1
Clinical8
  • Moreover, xenotransplantation accurately predicted results in canine-to-canine allogeneic transplantation experiments, an important pre-clinical model for future human clinical trials. (biomedcentral.com)
  • This project represents a pre-clinical model for gene transfer into hematopoietic stem cells. (nih.gov)
  • The long-term objective is to develop strategies that will allow levels of expression of CD18 in hematopoietic cells of children with leukocyte adhesion deficiency (LAD) that are sufficient to reverse the clinical phenotype. (nih.gov)
  • The successful application of HSCT for diseases such as leukemia, lymphoma, myeloma, and inherited blood disorders underscored its broad applicability in clinical practice (Snowden et al. (revistadehematologia.org.mx)
  • He has successfully taken research discoveries to the bedside and has been instrumental in establishing many of the clinicial HSCT procedures and current clinical trials including HSCT for severe autoimmune diseases and HIV. (edu.au)
  • Ma DD , 2007 , 'Expression of Neurofilament Proteins in Adult Bone Marrow Mesenchymal Stem Cells and Embryonic Stem Cells and Their Clinical Potential' , in Davenport LP (ed. (edu.au)
  • A consequence of the latter cell flow was recently demonstrated in a clinical study in cord blood transplantation. (ashpublications.org)
  • The success of the tool, described recently in the journal Transplantation and Cellular Therapy , demonstrates how a unique embedded informatics team can rapidly build and implement applications that are useful in a clinical setting. (azolifesciences.com)
Transplants1
Graft4
  • Infection and graft-versus-host disease are major complications of allogeneic HSCT. (wikipedia.org)
  • Newer research indicates that other graft-versus-host disease target organs include the immune system (the hematopoietic system , e.g., the bone marrow and the thymus ) itself, and the lungs in the form of immune-mediated pneumonitis . (wikipedia.org)
  • In addition, we are committed to graft engineering and vaccine development to enhance the ability of transplantation to control blood diseases. (harvard.edu)
  • Various factors including age, sex, performance status (PS), disease status, cytogenetic risk, donor type, graft source, sex mismatch between the donor and the recipient, and year of transplantation were all shown to impact OS 2 . (apbmt.org)
Mortality3
  • For other cancers such as acute myeloid leukemia, though, the reduced mortality of the autogenous relative to allogeneic HSCT may be outweighed by an increased likelihood of cancer relapse and related mortality, so the allogeneic treatment may be preferred for those conditions. (wikipedia.org)
  • For R/R-AML, HLA-id sibling donors remain the gold standard, when available, due to higher mortality in Haplo without significant gain in disease control. (unisr.it)
  • The primary endpoint will assess the effect of EN on D100 mortality. (biomedcentral.com)
Complications1
  • If one of the brothers and sisters is compatible, we speak about geno-identical allogeneic transplantation having the advantage of reducing the complications post-transplantation. (longdom.org)
Allogeneic HSCT2
  • According to the authors, "our results suggested that allogeneic HSCT for hepatitis-associated aplastic anemia would provide favorable survival. (hematologyadvisor.com)
  • Allogeneic HSCT is performed for a small number of inborn errors of metabolism (IEM). (ashpublications.org)
Cord-blood1
  • Namely, recipients sharing one or more HLA Ags with their cord blood donor inherited paternal Ags had reduced relapse rates compared with those who did not. (ashpublications.org)
Prophylaxis1
  • Despite pre- and post-HSCT anti-infective prophylaxis with cotrimoxazole, colistin, acyclovir, and fluconazole, Enterobacter cloacae sepsis was diagnosed on day 2. (cdc.gov)
Immune5
  • The immune system cells come from the bone marrow where they grow from special cells called stem cells. (zhihuiya.com)
  • This lets the cells of the donor go into the bone marrow and produce normal immune cells. (zhihuiya.com)
  • PHASES OF IMMUNE RECOVERY specialists, HSCT unit and clinic staff, and public health pro- fessionals. (cdc.gov)
  • 1957). This pioneering work laid the foundation for the exploration of hematopoietic stem cells and their role in treating diseases of the blood and immune system. (revistadehematologia.org.mx)
  • HSCT offers a way to reset the immune system, providing a novel approach to treating conditions such as multiple sclerosis, systemic sclerosis, and rheumatoid arthritis (Swart et al. (revistadehematologia.org.mx)
Aplastic anemia1
  • There was a median of 6.0 months (range, 0.5-430.8) between hepatitis-associated aplastic anemia diagnosis and HSCT. (hematologyadvisor.com)
Curative treatment1
  • The Allogeneic bone-marrow transplantation represents the only curative treatment and requires a compatible donor HLA. (longdom.org)
Proliferate2
Abstract1
  • However, current electronic health record (EHR) systems lack the capability to calculate engraftment automatically, so staff need to manually abstract these data from patient charts. (azolifesciences.com)
Recipients1
  • The inhibitory KIRs 2DL1 (CD158a), 2DL2/3 (CD158b), and 3DL1 (CD158e1) are such surface receptors and allow adoptively transferred donor NK cells to exert potent antileukemic effects if the cognate HLA class I ligands are absent in the recipients [ 3 ]. (biomedcentral.com)
Hematological1
HSCs1
  • Hematopoietic stem cells (HSCs) are very rare cells, representing approximately one in 100,000 bone marrow (BM) cells in the adult. (longdom.org)
Infection1
  • There was no difference in transplantation-related toxicity (TRT) in terms of infection, hepatic dysfunction, oral mucositis, and engraftment syndrome between the haploidentical HSCT and HLA-matched HSCT groups. (blood-genomics.com)
Adult2
  • In murine-to-murine transplantation experiments, CXCR4 expression marks a population of adult murine satellite cells with robust engraftment potential in mdx mice, and CXCR4-positive murine muscle-derived SP cells home more effectively to dystrophic muscle after intra-arterial delivery in mdx 5cv mice. (biomedcentral.com)
  • Since its establishment in 2010, the Adult AML Working Group within the JSHCT has been using this registry data to complete several studies focusing on various aspects of HCT in adults with AML, with particular attention paid to patient-, disease-, and transplantation-related factors. (apbmt.org)
Alloreactive donor1
  • The lack of benefit may result from insufficient numbers and limited persistence of alloreactive donor NK cells but does not preclude its potential usefulness during other phases of therapy, or in combination with other immunotherapeutic agents. (biomedcentral.com)
Haploidentical donors1
  • Transduced cells were transfused either after day +60 (matched donors) or on day +42 (haploidentical donors). (frontiersin.org)
Liver transplantation1
  • Median ages of liver transplantation and diagnosis of PTLD were 9.5 months (range: 6-51 months) and 31.2 months (range: 10-114 months), respectively. (hku.hk)
Median2
  • Median age at HSCT was 52 (range 18-74) years. (unisr.it)
  • Median duration from time of transplantation to diagnosis of PTLD was 18.4 months (range: 4.1-65 months). (hku.hk)
Lymphoproliferative disorders1
Cyclophosphamide1
  • Allogenic HSCT was performed in August 2006 after conditioning with total body irradiation (200 cGy, day -8 before HSCT surgery), fludarabine (days -7 to -4), antithymocyte globulin (days -4 to -1), and cyclophosphamide (days -3 to -2). (cdc.gov)
Centre2
  • We report on the NEPHA trial: an open-label, prospective, randomised, multi-centre study on two parallel groups, which has been designed to evaluate the effect of EN compared to PN on early toxicity after an allo-HSCT procedure. (biomedcentral.com)
  • An experienced multidisciplinary team in close consultation with the primary transplantation centre should perform the rehabilitation therapy. (mdpi.com)
Diseases2
  • This study will use lower doses of a drug called busulfan and lower doses of radiation than what are currently being used in other kinds of bone marrow transplantation for other diseases. (zhihuiya.com)
  • To date ex vivo gene therapy in hematopoietic disease has only been successful in diseases in which the transgene carries a selective advantage. (nih.gov)
Recipient1
  • The biological questions with MonoMAC center around whether the individual leukocyte compartments that are lost in MonoMAC (B-lymphocytes, NK cells, and monocytes) will be constituted with HSCT, and whether the residual recipient T-lymphocytes will represent an impediment to engraftment. (nih.gov)
Proliferation2
  • However, diprotin A, a positive modulator of CXCR4-SDF-1 binding, significantly enhanced engraftment and stimulated sustained proliferation of donor cells in vivo . (biomedcentral.com)
  • Diprotin A stimulation of CXCR4, however, significantly increased the number of canine dystrophin-positive muscle fibers and canine-derived satellite cells by enhancing donor cell proliferation. (biomedcentral.com)